<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gain-of-function mutations in fibroblast growth factor receptor-3 (FGFR3) lead to several types of human <z:hpo ids='HP_0002652'>skeletal dysplasia</z:hpo> syndromes including <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, hypochondroplasia and thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (TD) </plain></SENT>
<SENT sid="1" pm="."><plain>Currently, there are no effective treatments for these <z:hpo ids='HP_0002652'>skeletal dysplasia</z:hpo> diseases </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we screened, using FGFR3 as a bait, a random 12-<z:chebi fb="7" ids="16670">peptide</z:chebi> phage library and obtained 23 positive clones that share identical amino acid sequences (VSPPLTLGQLLS), named as <z:chebi fb="7" ids="16670">peptide</z:chebi> P3 </plain></SENT>
<SENT sid="3" pm="."><plain>This <z:chebi fb="7" ids="16670">peptide</z:chebi> had high binding specificity to the extracellular domain of FGFR3 </plain></SENT>
<SENT sid="4" pm="."><plain>P3 inhibited tyrosine kinase activity of FGFR3 and its typical downstream molecules, extracellular signal-regulated kinase/<z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase </plain></SENT>
<SENT sid="5" pm="."><plain>P3 also promoted proliferation and chondrogenic differentiation of cultured ATDC5 chondrogenic cells </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, P3 alleviated the bone <z:hpo ids='HP_0001510'>growth retardation</z:hpo> in bone rudiments from mice mimicking human thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> type II (TDII) </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, P3 reversed the <z:mp ids='MP_0002058'>neonatal lethality</z:mp> of TDII mice </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, this study identifies a novel inhibitory <z:chebi fb="7" ids="16670">peptide</z:chebi> for FGFR3 signaling, which may serve as a potential therapeutic agent for the treatment of FGFR3-related <z:hpo ids='HP_0002652'>skeletal dysplasia</z:hpo> </plain></SENT>
</text></document>